Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Metuchen Pharmaceuticals, LLC.
WARNING LETTER
•Metuchen Pharmaceuticals, LLC.•September 3, 2019

Metuchen Pharmaceuticals, LLC. – FDA Warning Letter, Sep 3, 2019

Record Details

The FDA's Office of Prescription Drug Promotion (OPDP) issued a Warning Letter to Metuchen Pharmaceuticals, LLC, regarding promotional materials for STENDRA® (avanafil) tablets. The review of a direct-to-consumer print ad (STEN-MET-28) and display banners (STEN-MET-02 and STEN-MET-06) revealed false or misleading claims about Stendra's risks and efficacy, misbranding the drug under the FD&C Act (21 U.S.C. 352(a) & (n); 321(n), 331(a); 21 CFR 202.1(e)(3)(ii), (iii); (e)(5); (e)(7)(viii)).

Specifically, the print ad suggested a new, unapproved use: "Treat ED and Reduce Risk of Heart Failure with a PDE-5 Inhibitor," for which Stendra lacks approval and adequate directions for use, further misbranding it (21 U.S.C. 352(f)(1); 331(a); 21 CFR 201.5; 201.100; 201.115; 201.128). This is concerning given Stendra's cardiovascular risks and contraindication in patients with New York Heart Association Class 2 or

Company
Metuchen Pharmaceuticals, LLC.
Inspection date
September 3, 2019
Product type
Drugs
Office
Office of Prescription Drug Promotion
Person
  • Robert Dean (Director)
View Company Profile

ID · 20fc6459-2221-47fd-8828-b662124b3517

Violation Codes10
21 U.S.C. 352(a)21 U.S.C. 352(n)21 U.S.C. 321(n)21 U.S.C. 352(f)(1)21 CFR 202.1(e)(3)(ii)21 CFR 202.1(e)(3)(iii)21 CFR 202.1(e)(5)21 CFR 202.1(e)(7)(viii)21 CFR 201.521 CFR 201.100

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Metuchen Pharmaceuticals, LLC.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.